Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer

Gastric Cancer

Volumn 13, Issue 4, 2010, Pages 245-250

  Tsushima, Takahiro ^a   Hironaka, Shuichi ^a,b   Boku, Narikazu ^a   MacHida, Nozomu ^a   Yamazaki, Kentaro ^a   Yasui, Hirofumi ^a   Taku, Keisei ^a   Fukutomi, Akira ^a   Onozawa, Yusuke ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Efficacy; Elderly; Gastric Cancer; S 1; Safety

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; AGE; AGED; ANEMIA; ANOREXIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; ANOREXIA; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FATIGUE; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 78650528070     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-010-0566-z     Document Type: Article

References (29)

1. N. Munoz S. Franceschi 1997 Epidemiology of gastric cancer and perspectives for prevention Salud Publica Mex 39 318 330 1:STN:280: DyaK2svnvVyisA%3D%3D 9337564
2. F. Kamangar G.M. Dores W.F. Anderson 2006 Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137 2150 10.1200/JCO.2005.05.2308 16682732
3. M. Inoue S. Tsugane 2005 Epidemiology of gastric cancer in Japan Postgrad Med J 81 419 424 1:STN:280:DC%2BD2Mzkslehsg%3D%3D 10.1136/pgmj.2004.029330 15998815
4. A.M. Murad F.F. Santiago A. Petroianu P.R. Rocha M.A. Rodrigues M. Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41 1:STN:280:DyaK3s3osVGqtQ%3D%3D 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P 8508427
5. B. Glimelius K. Hoffman U. Haglund O. Nyren P.O. Sjoden 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 190 1:STN:280:DyaK2c3kt1KrsA%3D%3D 8186165
6. S. Pyrhonen T. Kuitunen P. Nyandoto M. Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 1:STN:280:DyaK2M7os1ertg%3D%3D 7533517
7. S.A. Cullinan C.G. Moertel T.R. Fleming J.R. Rubin J.E. Krook L.K. Everson, et al. 1985 A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin JAMA 253 2061 2067 1:STN:280:DyaL2M7jsFalsw%3D%3D 10.1001/jama.253.14.2061 2579257
8. J.A. Wils H.O. Klein D.J. Wagener H. Bleiberg H. Reis F. Korsten, et al. 1991 Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group J Clin Oncol 9 827 831 1:STN:280:DyaK3M3gt1ajuw%3D%3D 2016625
9. D. Kelsen O.T. Atiq L. Saltz D. Niedzwiecki D. Ginn D. Chapman, et al. 1992 FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 541 548 1:STN:280:DyaK387ptl2lsw%3D%3D 1548519
10. G. Cocconi M. Bella S. Zironi R. Algeri F. Di Costanzo V. De Lisi, et al. 1994 Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research J Clin Oncol 12 2687 2693 1:STN:280:DyaK2M%2FotFyisw%3D%3D 7989945
11. A. Webb D. Cunningham J.H. Scarffe P. Harper A. Norman J.K. Joffe, et al. 1997 Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261 267 1:CAS:528:DyaK2sXnsV2msA%3D%3D 8996151
12. U. Vanhoefer P. Rougier H. Wilke M.P. Ducreux A.J. Lacave E. Van Cutsem, et al. 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657 1:CAS:528:DC%2BD3cXls12iurk%3D 10894863
13. N.K. Kim Y.S. Park D.S. Heo C. Suh S.Y. Kim K.C. Park, et al. 1993 A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813 3818 1:STN:280: DyaK3s3osVCqsg%3D%3D 10.1002/1097-0142(19930615)71:12<3813::AID- CNCR2820711205>3.0.CO;2-5 8508349
14. S.A. Cullinan C.G. Moertel H.S. Wieand M.J. O'Connel M.A. Poon J.E. Krook, et al. 1994 Controlled evaluation of three drug combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer J Clin Oncol 12 412 416 1:STN:280:DyaK2c7lslKhsw%3D%3D 8113849
15. A. Ohtsu Y. Shimada K. Shirao N. Boku I. Hyodo H. Saito, et al. 2003 Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54 59 1:CAS:528:DC%2BD2cXpsVWru7k%3D 10.1200/JCO.2003.04.130 12506170
16. T. Shirasaka Y. Shimamoto H. Ohshimo M. Yamaguchi T. Kato K. Yonekura, et al. 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557 1:CAS:528:DyaK28Xltleru78%3D 10.1097/00001813-199607000-00010 8862723
17. N. Boku S. Yamamoto H. Fukuda K. Shirao T. Doi A. Sawaki, et al. 2009 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063 1069 1:CAS:528:DC%2BD1MXhtlGit7bI 10.1016/S1470-2045(09)70259-1 19818685
18. W. Koizumi H. Narahara T. Hara A. Takagane T. Akiya M. Takagi, et al. 2007 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 10.1016/S1470-2045(08)70035-4
19. Imamura H, Ishii H, Tsuburaya A, Hatake K, Imamoto H, Esaki T, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC 0301/TOP-002). ASCO-GI 2008;Abstract no. 5.
20. S.M. Lichtman H. Wildiers E. Chatelut C. Steer D. Budman V.A. Morrison, et al. 2007 International Society Of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients - an analysis of the medical literature J Clin Oncol 25 1832 1843 1:CAS:528:DC%2BD2sXmtl2itLc%3D 10.1200/JCO.2007.10.6583 17488981
21. L. Repetto L. Balducci 2002 A case of geriatric oncology Lancet Oncol 3 289 297 10.1016/S1470-2045(02)00730-1 12067806
22. S.M. Lichtman M.K. Boparai 2008 Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy Curr Treat Options Oncol 9 191 203 10.1007/s11864-008-0060-6 18663583
23. A. Hurria S.M. Lichtman 2008 Clinical pharmacology of cancer therapies in older adults Br J Cancer 98 517 522 1:CAS:528:DC%2BD1cXhs1Krsbw%3D 10.1038/sj.bjc.6604201 18256586
24. J.L. Lee Y.K. Kang H.J. Kang K.H. Lee D.Y. Zang B.Y. Ryoo, et al. 2008 A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer Br J Cancer 99 584 590 1:CAS:528:DC%2BD1cXpslWrsbc%3D 10.1038/sj.bjc.6604536 18665164
25. W. Koizumi T. Akiya A. Sato T. Sakuyama E. Sasaki T. Tomidokoro, et al. 2010 Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group Study Cancer Chemother Pharmacol 65 1093 1099 1:CAS:528:DC%2BC3cXjtlalsL4%3D 10.1007/s00280-009-1114-6 19727730
26. R.D. Lindeman J. Tobin N.W. Shock 1985 Longitudinal studies of decline in renal function with age J Am Geriatr Soc 33 278 285 1:STN:280: DyaL2M7otlKgsw%3D%3D 3989190
27. K. Tatsumi M. Fukushima T. Shirasaka S. Fujii 1987 Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748 755 1:CAS:528:DyaL2sXlvFSntL8%3D 3114201
28. K. Hirata N. Horikoshi K. Aiba M. Okazaki R. Denno K. Sasaki, et al. 1999 Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000 2005 1:STN:280:DyaK1MvgtVSmtQ%3D%3D 10473078
29. F. Nagashima A. Ohtsu S. Yoshida K. Ito 2005 Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer Gastric Cancer 8 6 11 10.1007/s10120-004-0306-3 15747168